Evidence for using Afinitor for colorectal cancer is weak – one small trial with weak results. There is some evidence from a small trial ( Altomare et al) reported in ASCO 2012 that some colorectal cancer patients whose tumors had gotten worse on all standard treatments can benefit from a combination of Afinitor® (everolimus) and Avastin® (bevacizumab). This was a small trial in 50 patients. It showed a tumor control rate of 47%. Median progression-free survival time was 2.28 months, median overall survival time was 7.87 months. 46 percent of patients had disease control that lasted a median of 6.1 months. There were no complete or partial responses. 8 had a minor response lasting median 4.1 months. 15 had stable disease lasting median 6.7 months.
Altomare et al., 2010 ASCO Annual Meeting Abstracts, Abstract # 3535, Phase II trial of bevacizumab (B) plus everolimus (E) for refractory metastatic colorectal cancer (mCRC).
nccn. colorectal cancer 2012
Afinitor, Prescribing Information 2012.
For Lay version see here